Spotlight on New Oncology Drugs: Access, Costs, and Use

Slideshow

Read compelling analyses of 5-year trends and projected changes in the oncology clinical drug pipeline, selected from the IMS Institute for Healthcare Informatics’ recent “Global Oncology Trend Report.”

Slides republished with permission from the IMS Institute for Healthcare Informatics. Visit theimsinstitute.org to view the full publication, “Global Oncology Trend Report: A Review of 2015 and Outlook to 2020.”

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content
Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Darolutamide/ADT Improves Efficacy in Older Metastatic HSPC Population

Russ Conroy
November 23rd 2025
Article

Subgroup data from the ARASENS trial support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC regardless of age.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Radiation ± Chemotherapy Shows Worse Short-Term QOL in Cervical Cancer

Russ Conroy
November 22nd 2025
Article

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Fertility-Sparing Surgery May Be Safe Despite Recurrence in Cervical Cancer

Tim Cortese
November 21st 2025
Article

Fertility-sparing surgery showed comparable efficacy vs hysterectomy in early-stage cervical cancer, with a 5-year RFS rate of 92% vs 96.4%, respectively.

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.

Subcutaneous Mosunetuzumab Earns EU Approval in R/R Follicular Lymphoma

Russ Conroy
November 21st 2025
Article

Pharmacokinetic data from the phase 1/2 GO29781 study support the European approval of subcutaneous mosunetuzumab in this follicular lymphoma population.